Your session is about to expire
← Back to Search
Radiation Therapy
GRID radiotherapy for Osteosarcoma
N/A
Waitlist Available
Led By Jose Penagaricano, MD
Research Sponsored by University of Arkansas
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
History of cytological or histological documentation of non-metastatic extremity osteosarcoma.
5-21 years of age.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up an average of 12 months
Awards & highlights
Study Summary
This trial is testing a new cancer treatment called GRID therapy on children with osteosarcoma. They will receive different doses of GRID therapy to find out what is the safest dose with the least side effects.
Eligible Conditions
- Osteosarcoma
- Radiation Poisoning
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ an average of 12 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~an average of 12 months
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Number of Participants With Toxicities Associated With GRID Radiotherapy
Trial Design
1Treatment groups
Experimental Treatment
Group I: GRID RadiotherapyExperimental Treatment1 Intervention
Patients will be treated with GRID Radiotherapy
Find a Location
Who is running the clinical trial?
University of ArkansasLead Sponsor
486 Previous Clinical Trials
150,352 Total Patients Enrolled
Jose Penagaricano, MDPrincipal InvestigatorUniversity of Arkansas
1 Previous Clinical Trials
Leslie Harrell, MDPrincipal InvestigatorUniversity of Arkansas
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Share this study with friends
Copy Link
Messenger